Bexagliflozin

Drug Profile

Bexagliflozin

Alternative Names: Bexagliflozin L-proline; EGT-0001442; EGT-0001474; EGT-1442; THR-1442

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator Theracos
  • Class Antihyperglycaemics; Glucosides; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 29 Jun 2017 Theracos plans a phase I trial for Type-2 diabetes mellitus (In volunteers) (NCT03197324)
  • 24 May 2017 Theracos plans a phase I trial in Healthy volunteers in USA (NCT03167411)
  • 19 Apr 2017 Theracos plans a phase III trial for Type-2 diabetes mellitus (Treatment-experienced) (NCT03115112)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top